Mary Caffrey
Mary Caffrey is the Executive Editor for The American Journal of Managed Care® (AJMC®). She joined AJMC® in 2013 and is the primary staff editor for Evidence-Based Oncology, the multistakeholder publication that reaches 22,000+ oncology providers, policy makers and formulary decision makers. She is also part of the team that oversees speaker recruitment and panel preparations for AJMC®'s premier annual oncology meeting, Patient-Centered Oncology Care®. For more than a decade, Mary has covered ASCO, ASH, ACC and other leading scientific meetings for AJMC readers.
Mary has a BA in communications and philosophy from Loyola University New Orleans. You can connect with Mary on LinkedIn.
Articles
Takeda’s Budesonide Oral Suspension Receives FDA Approval for EoE
FDA has approved budesonide oral suspension to treat patients 11 years of age and older with eosinophilic esophagitis (EoE). The oral therapy, to be sold as Eohilia, will be available by the end of February, according to sponsor Takeda.
Priority Review Granted for Trastuzumab Deruxtecan; Would Be First Tumor-Agnostic ADC
A tumor-agnostic approval would be a significant development in the advance of antibody-drug conjugates (ADCs), which are designed to deliver a potent, cancer-fighting payload into a tumor while sparing nearby tissues.
First-Line Tiragolumab With Atezolizumab Plus Chemo Improves PFS, OS in Patients With ESCC
Treatment with both PD-1 and TIGIT immunotherapy alongside chemotherapy demonstrated improved progression-free (PFS) and overall survival (OS) compared with chemotherapy alone in patients with esophageal squamous cell carcinoma (ESCC).
Study Finds Huge Gap Between Clinical Trial Data and Real-World Outcomes in Multiple Myeloma
Real-world patients were on average older and had more comorbidities than those in clinical trials, factors previously seen in comparisons between patients in clinical trials and real-world settings.
Data Show Trend Toward Improved Persistence After 6 Months With Oral MDS Regimen
The authors concluded that the data support consideration of the oral regimen of decitabine and cedazuridine to reduce the treatment burden associated with intraveous or subcutaneous hypomethylating agents in patients with myelodysplastic syndromes (MDS).
